富士莱1月22日获融资买入684.40万元，融资余额6463.88万元

Core Viewpoint - Fujilai Pharmaceutical Co., Ltd. has shown a mixed performance in terms of financing and stockholder metrics, with a notable increase in net profit despite a modest rise in revenue [2][3]. Financing Summary - On January 22, Fujilai's stock price increased by 0.48%, with a trading volume of 77.86 million yuan. The financing buy-in amount was 6.84 million yuan, while the financing repayment was 9.22 million yuan, resulting in a net financing outflow of 2.37 million yuan [1]. - As of January 22, the total financing and securities lending balance for Fujilai was 64.66 million yuan, with the financing balance at 64.63 million yuan, accounting for 1.89% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1]. - In terms of securities lending, Fujilai repaid 3,000 shares on January 22, with no shares sold, resulting in a securities lending balance of 2.24 million yuan, which is above the 90th percentile level over the past year, indicating a high position [1]. Business Performance Summary - For the period from January to September 2025, Fujilai achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to the parent company was 73.40 million yuan, showing a significant year-on-year increase of 430.16% [2]. - The main business revenue composition includes: 66.02% from alpha-lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplementary products [1]. Shareholder and Dividend Information - As of January 20, the number of Fujilai shareholders reached 10,000, an increase of 2.94% from the previous period, while the average circulating shares per person decreased by 2.86% to 8,862 shares [2]. - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Yinhai Kangle Stock A (519673) was the ninth largest shareholder, holding 178,100 shares as a new shareholder [3].